Kazia Therapeutics Limited, a clinical-stage biotechnology company, has announced a significant development in their research on paxalisib, their lead oncology therapeutic. The company has initiated a Phase 1b clinical trial to evaluate the efficacy of paxalisib in combination with checkpoint inhibitors and chemotherapy for patients with advanced breast cancer. This announcement follows the publication of preclinical research in the journal Molecular Cancer Therapeutics, which highlighted paxalisib's potential to overcome immunotherapy resistance, particularly in triple-negative breast cancer. The preclinical data, conducted by the QIMR Berghofer Medical Research Institute, demonstrated that paxalisib could enhance immune response and work synergistically with immune checkpoint inhibitors. The results of this clinical trial will be presented in the future, as the trial progresses.